Axogen issued a corrected version of its investor presentation on September 10, 2026, replacing the presentation previously furnished to investors. The correction matters because investors are being directed to an updated presentation while Merger materials concerning BioCircuit Technologies include information about the transaction’s terms.

Key Highlights

  • The corrected investor presentation is dated September 10, 2026.
  • The merger agreement is dated September 9, 2026.
  • Michelle Jarrard is named as representative of BioCircuit Technologies’ equityholders.

Axogen, Inc. (NASDAQ: AXGN) furnished a corrected version of its investor presentation dated September 10, 2026. The updated presentation replaces the version previously furnished by the company. Axogen identified it as a corrected version of the presentation previously.

BioCircuit Merger Terms Included The

materials also include an agreement and plan of merger dated September 9, 2026. The parties named are Axogen, Omega Merger Sub, Inc. BioCircuit Technologies, Inc. and Michelle Jarrard, acting solely as representative of BioCircuit Technologies’ equityholders. The merger agreement was included to provide investors with information about its terms. Its representations, warranties and covenants were made for purposes of that agreement and as of specified dates.

Investor Information The agreement states that Omega Merger Sub, Inc.

is a Wholly Owned Subsidiary of Axogen and that BioCircuit Technologies is the company involved in the merger. The materials identify Michelle Jarrard as the equityholders’ representative. Axogen’s corrected investor presentation is dated September 10, 2026, while the merger agreement is dated September 9, 2026.